Inhibitory effects of rapamycin on the different stages of hepatic fibrosis

World Journal of Gastroenterology

Volumn 20, Issue 23, 2014, Pages 7452-7460

  Kim, Yun Jeung ^a   Lee, Eaum Seok ^a   Kim, Seok Hyun ^a   Lee, Heon Young ^a   Noh, Seung Moo ^a   Kang, Dae Young ^a   Lee, Byung Seok ^a  

^a Chungnam National University   (South Korea)

Author keywords

Liver cirrhosis; Platelet derived growth factor; Ribosomal protein S6 kinases; Sirolimus; Transforming growth factor beta

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYTOKERATIN; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; S6 KINASE; TRANSFORMING GROWTH FACTOR BETA1; BIOLOGICAL MARKER; TGFB1 PROTEIN, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DISEASE SEVERITY; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RAT; STAGING; WESTERN BLOTTING; ANIMAL; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; RATS, WISTAR; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIROLIMUS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84902668626     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i23.7452     Document Type: Article

References (36)

1. Friedman SL. Liver fibrosis--from bench to bedside. J Hepatol 2003; 38 Suppl 1: S38-S53 [PMID: 12591185]
2. Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int 2013; 110: 85-91 [PMID: 23451000 DOI: 10.3238/ arztebl.2013.0085]
3. Abdel-Aziz G, Lebeau G, Rescan PY, Clément B, Rissel M, Deugnier Y, Campion JP, Guillouzo A. Reversibility of hepatic fibrosis in experimentally induced cholestasis in rat. Am J Pathol 1990; 137: 1333-1342 [PMID: 2260623]
4. Aronson DC, Chamuleau RA, Frederiks WM, Gooszen HG, Heijmans HS, James J. Reversibility of cholestatic changes following experimental common bile duct obstruction: fact or fantasy? J Hepatol 1993; 18: 85-95 [PMID: 8340613]
5. Lee BS, Kim NJ, Jeong HY, Lee HY, Kang DY, Noh SM. Changes in serum cytokine concentration: a morphological study of liver cirrhosis induced by common bile duct ligation in rats. Korean J Intern Med 2003; 18: 6-12 [PMID: 12760262]
6. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993; 92: 2597-2601 [PMID: 8254017]
7. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292 [PMID: 7935686]
8. Saile B, Matthes N, Knittel T, Ramadori G. Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells. Hepatology 1999; 30: 196-202 [PMID: 10385656]
9. Pinzani M, Knauss TC, Pierce GF, Hsieh P, Kenney W, Dubyak GR, Abboud HE. Mitogenic signals for plateletderived growth factor isoforms in liver fat-storing cells. Am J Physiol 1991; 260: C485-C491 [PMID: 2003575]
10. Borkham-Kamphorst E, Kovalenko E, van Roeyen CR, Gassler N, Bomble M, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury. Lab Invest 2008; 88: 1090-1100 [PMID: 18663351 DOI: 10.1038/labinvest.2008.71]
11. Bridle KR, Li L, O'Neill R, Britton RS, Bacon BR. Coordinate activation of intracellular signaling pathways by insulin-like growth factor-1 and platelet-derived growth factor in rat hepatic stellate cells. J Lab Clin Med 2006; 147: 234-241 [PMID: 16697771]
12. Wong L, Yamasaki G, Johnson RJ, Friedman SL. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994; 94: 1563-1569 [PMID: 7929832]
13. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell 1992; 69: 1227-1236 [PMID: 1377606]
14. Yang X, Yang C, Farberman A, Rideout TC, de Lange CF, France J, Fan MZ. The mammalian target of rapamycinsignaling pathway in regulating metabolism and growth. J Anim Sci 2008; 86: E36-E50 [PMID: 17998426]
15. Gaben AM, Saucier C, Bedin M, Barbu V, Mester J. Rapamycin inhibits cdk4 activation, p 21(WAF1/CIP1) expression and G1-phase progression in transformed mouse fibroblasts. Int J Cancer 2004; 108: 200-206 [PMID: 14639603]
16. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivières S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998; 273: 14424-14429 [PMID: 9603954]
17. Bridle KR, Popa C, Morgan ML, Sobbe AL, Clouston AD, Fletcher LM, Crawford DH. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl 2009; 15: 1315-1324 [PMID: 19790156 DOI: 10.1002/lt.21804]
18. Biecker E, De Gottardi A, Neef M, Unternährer M, Schneider V, Ledermann M, Sägesser H, Shaw S, Reichen J. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J Pharmacol Exp Ther 2005; 313: 952-961 [PMID: 15769867]
19. Carpino G, Morini S, Ginanni Corradini S, Franchitto A, Merli M, Siciliano M, Gentili F, Onetti Muda A, Berloco P, Rossi M, Attili AF, Gaudio E. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liver Dis 2005; 37: 349-356 [PMID: 15843085]
20. Ballardini G, Fallani M, Biagini G, Bianchi FB, Pisi E. Desmin and actin in the identification of Ito cells and in monitoring their evolution to myofibroblasts in experimental liver fibrosis. Virchows Arch B Cell Pathol Incl Mol Pathol 1988; 56: 45-49 [PMID: 2907200]
21. Gibelli NE, Tannuri U, Mello ES. Immunohistochemical studies of stellate cells in experimental cholestasis in newborn and adult rats. Clinics (Sao Paulo) 2008; 63: 689-694 [PMID: 18925331]
22. Carvalho SN, Lira DC, Oliveira GP, Thole AA, Stumbo AC, Caetano CE, Marques RG, Carvalho L. Decreased collagen types I and IV, laminin, CK-19 and α-SMA expression after bone marrow cell transplantation in rats with liver fibrosis. Histochem Cell Biol 2010; 134: 493-502 [PMID: 20963436 DOI: 10.1007/s00418-010-0746-2]
23. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669 [PMID: 18471545 DOI: 10.1053/ j.gastro.2008.03.003]
24. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206 [PMID: 21497738 DOI: 10.1016/j.bpg.2011.02.005]
25. Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248 [PMID: 16699448]
26. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323 [PMID: 14523139]
27. Gao Y, Xu X, Ding K, Liang Y, Jiang D, Dai H. Rapamycin inhibits transforming growth factor β1-induced fibrogenesis in primary human lung fibroblasts. Yonsei Med J 2013; 54: 437-444 [PMID: 23364979 DOI: 10.3349/ymj.2013.54.2.437]
28. McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, Neri M, O'Leary JG, Davis GL, Levy MF, Goldstein RM, Klintmalm GB. Limiting hepatitis C virus progression in liver transplant recipients using sirolimusbased immunosuppression. Am J Transplant 2011; 11: 2379-2387 [PMID: 21967703 DOI: 10.1111/j.1600-6143.]
29. Kim M, Curry MP, Rogers CC. Impact of sirolimus duration on hepatitis C related fibrosis progression in liver transplant recipients. Am J Transplant 2012; 12: 1356-1357 [PMID: 22299778]
30. Kelly MA, Kaplan M, Nydam T, Wachs M, Bak T, Kam I, Zimmerman MA. Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience. Transplant Proc 2013; 45: 3325-3328 [PMID: 24182811 DOI: 10.1016/j.transproceed]
31. Chatzipantelis P, Lazaris AC, Kafiri G, Papadimitriou K, Papathomas TG, Nonni A, Patsouris ES. Cytokeratin-7, cytokeratin-19, and c-Kit: Immunoreaction during the evolution stages of primary biliary cirrhosis. Hepatol Res 2006; 36: 182-187 [PMID: 16963314]
32. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992; 90: 1-7 [PMID: 1634602]
33. Gäbele E, Reif S, Tsukada S, Bataller R, Yata Y, Morris T, Schrum LW, Brenner DA, Rippe RA. The role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation. J Biol Chem 2005; 280: 13374-13382 [PMID: 15677443]
34. Nishioka C, Ikezoe T, Yang J, Gery S, Koeffler HP, Yokoyama A. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells. Int J Cancer 2009; 125: 1710-1720 [PMID: 19507250 DOI: 10.1002/ijc.24472]
35. Fenton TR, Gout IT. Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol 2011; 43: 47-59 [PMID: 20932932 DOI: 10.1016/j.biocel.2010.09.018]
36. Zhu J, Wu J, Frizell E, Liu SL, Bashey R, Rubin R, Norton P, Zern MA. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999; 117: 1198-1204 [PMID: 10535884]